Working… Menu
Trial record 1 of 1 for:    POD1UM 201 - INCMGA 0012-201
Previous Study | Return to List | Next Study

A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03599713
Recruitment Status : Active, not recruiting
First Posted : July 26, 2018
Last Update Posted : September 10, 2021
Information provided by (Responsible Party):
Incyte Corporation

Brief Summary:
The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced/metastatic Merkel cell carcinoma (MCC).

Condition or disease Intervention/treatment Phase
Metastatic Merkel Cell Carcinoma Drug: Retifanlimab Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 106 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma (POD1UM-201)
Actual Study Start Date : February 25, 2019
Actual Primary Completion Date : June 16, 2021
Estimated Study Completion Date : September 15, 2023

Arm Intervention/treatment
Experimental: INCMGA00012 Drug: Retifanlimab
INCMGA00012 administered at the recommended Phase 2 dose by IV infusion once every 28 days.
Other Names:
  • MGA012
  • INCMGA00012

Primary Outcome Measures :
  1. Overall Response Rate (ORR) [ Time Frame: Baseline up to approximately 8 months ]
    Defined as the percentage of participants with an objective response (complete response [CR] or partial response [PR]) according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as determined by independent central radiographic review (ICR).

Secondary Outcome Measures :
  1. Duration of Response (DOR) [ Time Frame: Up to approximately 2 years ]
    Defined as the time from an initial objective response (CR or PR) according to RECIST v1.1 until disease progression as determined by ICR or death due to any cause.

  2. Disease Control Rate (DCR) [ Time Frame: Up to approximately 2 years ]
    Defined as the proportion of participants with either an objective response or stable disease lasting at least 6 months.

  3. Progression Free Survival (PFS) [ Time Frame: Up to approximately 2 years ]
    Defined as the time from the start of therapy until disease progression as determined by the ICR or death due to any cause.

  4. Overall survival (OS) [ Time Frame: Up to approximately 2 years ]
    Defined as the time from the start of therapy until death due to any cause.

  5. Number of Treatment-Emergent Adverse Events (TEAE) [ Time Frame: Up to approximately 2 years ]
    Adverse events reported for the first time or worsening of a pre-existing event after first dose of study treatment.

  6. Cmax of INCMGA00012 [ Time Frame: Up to approximately 6 months ]
    Maximum observed serum concentration.

  7. tmax of INCMGA00012 [ Time Frame: Up to approximately 6 months ]
    Time to maximum concentration.

  8. Cmin of INCMGA00012 [ Time Frame: Up to approximately 6 months ]
    Minimum observed serum concentration over the dose interval.

  9. AUCt of INCMGA00012 [ Time Frame: Up to approximately 6 months ]
    Area under the serum concentration-time curve.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed informed consent.
  • Diagnosis of MCC with distant metastatic disease or recurrent, advanced locoregional disease not amenable to surgery or radiation
  • Eastern Cooperative Oncology Group performance status of 0 to 1.
  • Measurable disease according to RECIST v1.1.
  • Availability of tumor tissue (fresh or archival) for central pathology review.
  • Willingness to avoid pregnancy or fathering children based on protocol-defined criteria.

Exclusion Criteria:

  • Prior systemic therapy for MCC, including chemotherapy and prior PD-1 or PD-L1-directed therapy.
  • Treatment with anticancer drugs or participation in another interventional clinical study within 21 days before the first administration of study drug.
  • Has not recovered to ≤ Grade 1 or baseline from toxic effects of prior therapy (with the exceptions for anemia not requiring transfusion support and any grade of alopecia) and/or complications from prior surgical intervention within 7 days before starting study treatment.
  • Radiation therapy administered within 2 weeks of first dose of study treatment or radiation therapy to the thoracic region that is > 30 Gy within 6 months of the first dose of study treatment.
  • Known central nervous system (CNS) metastases and/or carcinomatous meningitis.
  • History of second malignancy within 3 years (with exceptions).
  • Laboratory values outside the protocol-defined range at screening.
  • Clinically significant pulmonary, cardiac, gastrointestinal or autoimmune disorders.
  • Active bacterial, fungal, or viral infections, including hepatitis A, B, and C.
  • Receipt of a live vaccine within 28 days of planned start of study therapy.
  • Current use of protocol-defined prohibited medication.
  • Known hypersensitivity to another monoclonal antibody that cannot be controlled with standard measures (eg, antihistamines and corticosteroids).
  • Inability or unlikely, in the opinion of the investigator, to comply with the Protocol requirements.
  • Participant who is pregnant or breastfeeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03599713

Show Show 65 study locations
Sponsors and Collaborators
Incyte Corporation
Layout table for investigator information
Study Director: Incyte Medical Monitor Incyte Corporation
Layout table for additonal information
Responsible Party: Incyte Corporation Identifier: NCT03599713    
Other Study ID Numbers: INCMGA 0012-201
First Posted: July 26, 2018    Key Record Dates
Last Update Posted: September 10, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Incyte Corporation:
Metastatic merkel cell carcinoma
anti-PD-1 antibody
immunoglobulin G4 (IgG4) monoclonal antibody
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Merkel Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Polyomavirus Infections
DNA Virus Infections
Virus Diseases
Tumor Virus Infections
Carcinoma, Neuroendocrine
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue